Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

3 Stocks You’ll Wish You Bought Before 2026

Notepad lists small-cap biotech, high-growth fintech, and niche retail stocks to buy before 2026.
AI Image Created Under the Direction of Shannon Tokheim

Key Points

  • These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
  • Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
  • Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
  • MarketBeat previews top five stocks to own in June.

Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.

The three stocks in this article are still small stocks; the largest market cap is just over $4 billion. However, they’ve made strong moves and proven the idea that time in the market is better than trying to time the market.

That said, if investors could see the future with absolute clarity, investing would be easy. Unfortunately, the future is rarely clear, and a bullish outcome is not inevitable. But the charts speak for themselves. Investors who bought these stocks and had the patience to hold them through some rough times are reaping the benefits today. Better still, the stocks may not be done moving higher.

Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst

Celcuity Stock Forecast Today

12-Month Stock Price Forecast:
$149.30
8.01% Upside
Moderate Buy
Based on 12 Analyst Ratings
Current Price$138.23
High Forecast$189.00
Average Forecast$149.30
Low Forecast$60.00
Celcuity Stock Forecast Details

Celcuity Inc. NASDAQ: CELC is a clinical-stage biotechnology company that recently delivered positive clinical data for its first-in-class PI3K/mTOR inhibitor that targets HR+/HER2 - metastatic breast cancer. The company’s pivotal Phase 3 VIKTORIA trial is underway, and there is a belief that the company could receive U.S. Food & Drug Administration (FDA) approval in 2026.

Investors have been front-running those results, pushing CELC stock up over 660%, with almost the entirety of those gains occurring since the end of July. At $99.30 as of this writing, the stock is within 3% of its consensus price target. However, Jeffries raised its price target on the stock to $134 from $108 on Dec. 2.

The biggest risk investors face is the financial cost of the commercialization phase. However, in its most recent earnings report, Celcuity showed a reinforced balance sheet with $455 million in cash, cash equivalents, and short-term investments. That was up about 72% year-over-year (YOY), and management believes that will be sufficient until the commercialization phase begins.

Fintech Disruptor Turning Revenue Growth Into Real Momentum

Dave Stock Forecast Today

12-Month Stock Price Forecast:
$325.88
42.64% Upside
Moderate Buy
Based on 14 Analyst Ratings
Current Price$228.46
High Forecast$365.00
Average Forecast$325.88
Low Forecast$290.00
Dave Stock Forecast Details

At a time when banks have less to offer many consumers, it’s easy to make the case for Dave Inc. NASDAQ: DAVE. This is a Los Angeles-based financial technology (fintech) company known for its Dave app.

The Dave app provides affordable, transparent financial tools that help its users, many of whom are living paycheck to paycheck, avoid overdraft fees, budget more effectively, and get access to short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS).

DAVE stock is up 120% in 2025, and analysts believe it’s got much more room to move higher. As of this writing, the stock is trading at $208.24, and the consensus price target is $304.25. That’s an upside of more than 46%.

Some investors could be getting nervous about the company’s forward price-to-earnings (P/E) ratio of around 119x. However, analysts are forecasting earnings growth of over 117% in the next 12 months. That kind of growth will easily allow for growth into that valuation.

Resale Retail Winner Riding a Massive Consumer Shift

ThredUp Stock Forecast Today

12-Month Stock Price Forecast:
$9.14
113.05% Upside
Moderate Buy
Based on 7 Analyst Ratings
Current Price$4.29
High Forecast$14.00
Average Forecast$9.14
Low Forecast$5.70
ThredUp Stock Forecast Details

It's been another rough year for consumer staples stocks, but ThreadUp Inc. NASDAQ: TDUP has been a notable exception. TDUP stock is up over 430% in 2025, and that’s despite a sell-off of over 29% in the three months ending Dec. 1.

The company operates as an online consignment store, which makes it the right stock at a time when many consumer budgets continue to be stretched. The thrift and resale market was a $49 billion industry in 2024 and is expected to grow to $74 billion by 2029.

TDUP stock is the smallest of the three stocks on this list, and short interest of over 17% means that traders are active. That said, the company’s Q3 earnings report showed strong YOY revenue growth and, more importantly, a record in new buyer acquisition and a 37% YOY increase in orders.

Admittedly, this could be a short-term play. However, the younger generation that makes up ThredUp’s core market will likely feel pinched for some time, which is likely why analysts give TDUP stock a consensus price target of $12.50, representing a 68% gain from its closing price on Dec. 1.

Should You Invest $1,000 in ThredUp Right Now?

Before you consider ThredUp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ThredUp wasn't on the list.

While ThredUp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Chris Markoch
About The Author

Chris Markoch

Associate Editor & Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Celcuity (CELC)
2.0858 of 5 stars
$138.23flatN/AN/AModerate Buy$149.30
Dave (DAVE)
4.4736 of 5 stars
$228.46flatN/A14.69Moderate Buy$325.88
ThredUp (TDUP)
3.5555 of 5 stars
$4.29flatN/AN/AModerate Buy$9.14
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines